Incretin-based therapies in patients with type 2 diabetes mellitus by using either the injection form of glucagon-like peptide-1 receptor (GLP-1R) agonists or the oral form of dipeptidyl peptidase-4 (DPP-4) inhibitors have been shown to increase the risk of thyroid cancer [1, 2]. This evidence concerns the gene GLP1R and thyroid gland carcinoma.